The combination of two well-known high blood pressure medicines did not result in unexpected patient benefits.
The U.S. Court of Appeals for the Federal Circuit has upheld a decision by the Patent Trial and Appeal Board denying as obvious over prior art an application to patent a method of co-administering two well-known antihypertensive agents to treat high blood pressure. While the manner in which the combined drugs achieved the reduction in blood pressure was unforeseen, the Board correctly determined that because the combined drugs yielded the same ultimate outcome as the individual compounds—lowering blood pressure in patients—the novel treatment was not patentable (In re Couvaras, June 14, 2023, Lourie, A.).
Case date: 14 June 2023
Case number: No. 22-1489
Court: United States Court of Appeals, Federal Circuit
A full summary of this case has been published on Kluwer IP Law.
_____________________________
To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe here.
Kluwer IP Law
The 2022 Future Ready Lawyer survey showed that 79% of lawyers think that the importance of legal technology will increase for next year. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?
Learn how Kluwer IP Law can support you.
